Company profile: Evidera
Data disruption and applying ‘enabled intelligence’ to convert the promise shown in clinical trials into real-world success.
For years one of the pharmaceutical industry’s biggest challenges has been converting the promise of results gained in a clinical trial setting into success in the real world. Are payers willing to pay for the treatment? Will the product show the same benefit to patients outside of a controlled scenario? What is the evidence that supports that the product has true value in the real world?
pharmaphorum spoke with Dr Radek Wasiak, VP and global head of peri- and post-approval studies at Evidera, a PPD business unit, to get his perspective on the changing dynamics and impact of data generation and analysis in the world of healthcare.